|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
In summary, here we confirmed significant association of the GSK3B CNV and bipolar disorder pointing out that the copy number and extension of the CNV varies among individuals.
|
24677591 |
2014 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies have identified GSK-3β as a potential therapeutic target in Alzheimer´s disease, bipolar disorder, stroke, more than 15 types of cancer, and diabetes.
|
29561817 |
2018 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggest that the GSK-3 beta is not associated with the development of schizophrenia and bipolar disorder in Korean population.
|
16289845 |
2006 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Lithium (Li), a mood stabilizer used to treat bipolar disorder (BP) symptoms has important anti-inflammatory effects by downregulation of glycogen synthase kinase-3 beta (GSK-3β).
|
29466765 |
2018 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
|
23440732 |
2013 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphism (SNP) rs334558 on the glycogen synthase kinase-3β (GSK3β) gene has been identified as a genetic risk loci associated with schizophrenia and bipolar disorder.
|
28099358 |
2017 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No association was detected between GSK3-beta -50 T/C SNP and the presence of bipolar illness.
|
14729229 |
2004 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The kinase glycogen synthase kinase 3 beta (GSK3beta) is considered as an interesting target of lithium, the classical drug used in BD.
|
16733521 |
2007 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lithium chloride, a classical treatment for bipolar disorder, has shown neuroprotective effects through glycogen synthase kinase-3β inhibition in a variety of central nervous system diseases, including stroke.
|
30336136 |
2018 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In summary, this meta-analysis suggests that the functional polymorphism -50C/T within the GSK3B gene promoter is unlikely to relate with BD risk.
|
24929537 |
2014 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These studies show region-specific abnormalities of both protein and mRNA expression of GSK-3β and β-catenin in postmortem brains of subjects with BP but not subjects with SZ.
|
25041379 |
2015 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
|
23440732 |
2013 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
We anticipate that the GSK-3β could be a druggable target for several incurable neuropsychiatric disorders including BD.
|
29283064 |
2018 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lithium ion, commonly used as the carbonate salt in the treatment of bipolar disorders, has been identified as an inhibitor of several kinases, including Glycogen Synthase Kinase-3β, for almost 20 years.
|
30667602 |
2019 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although Glycogen synthase kinase 3 beta (GSK3β) has been suggested to play a role in the pathophysiology of BD since it is inhibited by lithium, it remains unknown how GSK3β activity might be involved.
|
30699850 |
2019 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
In summary, this meta-analysis suggests that the functional polymorphism -50C/T within the GSK3B gene promoter is unlikely to relate with BD risk.
|
24929537 |
2014 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Baseline mRNA levels of glycogen synthase kinase 3 beta (GSK3β) and collapsin response mediator protein 1 (CRMP1) genes were significantly associated with BD status and with severity of mood symptoms.
|
29666369 |
2018 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism (SNP) (-50 T/C) falling into the effective promoter region (nt -171 to +29) of the gene coding for glycogen synthase kinase 3-beta (GSK3-beta) has been linked with different age at onset of bipolar illness and with different antidepressant effects of total sleep deprivation.
|
15694273 |
2005 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The findings suggest that seemingly disparate candidate genes for SZ and BD can be incorporated into a common molecular network revolving around GSK3β/β-catenin signaling.
|
20615089 |
2010 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to investigate the effects of ongoing long-term lithium treatment and GSK-3β promoter rs334558 polymorphism on regional gray matter (GM) volumes of patients with BD.
|
25345732 |
2015 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In summary, here we confirmed significant association of the GSK3B CNV and bipolar disorder pointing out that the copy number and extension of the CNV varies among individuals.
|
24677591 |
2014 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In a prospective 6-12 month follow-up study, GSK- 3β activity in peripheral blood mononuclear cells was measured concurrently with cognitive performance assessed using a comprehensive test battery in 27 patients with BD-I in early and late remission following a manic or mixed episode.
|
29433844 |
2018 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
We suggest that GSK3-β inhibition and lithium could counteract the detrimental influences of BD on WM structure, with specific benefits resulting from effects on specific WM tracts contributing to the functional integrity of the brain and involving interhemispheric, limbic, and large frontal, parietal, and fronto-occipital connections.
|
22990942 |
2013 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We studied whether lymphocyte GSK-3β activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls.
|
28106616 |
2017 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Homozygotes for the mutant allele of GSK3-beta promoter (-50T/C) SNP showed a later onset of bipolar illness, and better acute effects of TSD treatment on perceived mood (as rated on VAS).
|
15351432 |
2004 |